Use of Ruxolitinib Cream Results in Economic Benefits Compared with Dupilumab in Treatment of Patients with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy
This model demonstrates that 1.5% ruxolitinib cream reduces treatment costs by over 80% compared to dupilumab in patients with moderate AD eligible for systemic therapy. Combined with comparable efficacy, these savings position ruxolitinib cream as a cost-effective treatment option.
Authors
- Raj Chovatiya (ORCID: https://orcid.org/0000-0001-6510-399X)
- J. Z. Liu (ORCID: https://orcid.org/0009-0002-6042-5476)
- Daniel Sturm (ORCID: https://orcid.org/0009-0001-4413-8429)
- Zelma C. Chiesa Fuxench (ORCID: https://orcid.org/0000-0003-0023-4176)
- Omar Noor
- Dilan Paranagama (ORCID: https://orcid.org/0000-0001-6162-1992)
- Haobo Ren
Institutions
- Rosalind Franklin University of Medicine and Science (US)
- University of Pennsylvania (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1007/s13555-025-01602-z
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incyte